Results 141 to 150 of about 107,868 (263)

Transcatheter Tricuspid Valve Replacement for Residual Tricuspid Regurgitation After TEER

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Residual or recurrent tricuspid regurgitation (TR) after prior transcatheter tricuspid edge‐to‐edge (T‐TEER) repair occurs in about 12% of patients within 1 year. Since surgical tricuspid valve repair or replacement is of high risk, treatment options remain scarce.
Fabian Voß   +14 more
wiley   +1 more source

Resource Allocation in the Pediatric Intensive Care Unit in Rwanda. [PDF]

open access: yesAnn Glob Health
Kelly T   +5 more
europepmc   +1 more source

Interventional Mitral Valve Edge‐to‐Edge Repair in Patients Above 85 Years of Age

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Mitral valve transcatheter‐edge‐to‐edge repair (M‐TEER) is routinely performed in patients with severe mitral regurgitation (MR) at high operative risk, frequently including elderly patients. Patients ≥ 85 years, however, are frequently excluded in clinical studies.
Florian Jürgens   +8 more
wiley   +1 more source

Analyzing zero‐truncated recurrent event data by stratified regression with time‐varying coefficients

open access: yesCanadian Journal of Statistics, EarlyView.
Abstract This article presents a strategy for conducting regression analysis of zero‐truncated recurrent event data. The research is partly motivated by a pediatric mental health care (PMHC) program based on administrative data. We are particularly interested in how the occurrence of an event depends on its past occurrences and the associated ...
Anqi A. Chen   +3 more
wiley   +1 more source

Clinical Model‐Informed Precision Dosing Consult Service for Accelerating Personalized Medication in Pediatric Patients

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Traditional dosing strategies often rely on a “one‐size‐fits‐all” paradigm, assuming an “average” patient with typical demographic and pharmacological characteristics. In reality, this often overlooks existing between‐patient variability and can lead to suboptimal drug exposure or toxicity. This issue is especially pronounced in pediatric patients, who
Zachary L. Taylor   +12 more
wiley   +1 more source

Fecal Microbiota Transplantation and Microbiota‐Based Therapeutics in Allogeneic Hematopoietic Stem Cell Transplantation: Current Evidence and Future Directions

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
The intestinal microbiome is a key regulator of immune homeostasis, metabolism, and epithelial barrier integrity. In patients with malignant hematological diseases, particularly those undergoing hematopoietic stem cell transplantation, microbiome perturbations by reduced diversity, pathobiont expansion, and loss of beneficial metabolites are common as ...
Bálint Gergely Szabó   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy